Consists of Clobetasol, Ofloxacin, Ornidazole, Terbinafine
|
||
Funzi MX Pregnancy |
||
Consists of Clobetasol, Ofloxacin, Ornidazole, Terbinafine
There is no data on adverse effects of Clobetasol (Funzi MX) on pregnancy and fetal development.
However, in the I trimester of pregnancy this medication is contraindicated, in II and III trimester can be used for prescription. If necessary to use during lactation it should be considered that with breast milk in small amounts canrenone (metabolite of spironolactone) excretes.
Category of the fetus by FDA - C.
Ofloxacin (Funzi MX) has been assigned to pregnancy category C by the FDA. Animal studies using high doses have revealed evidence of fetotoxicity and teratogenicity. There are no controlled data in human pregnancy. Surveillance studies have not reported an increased risk of major birth defects. However, cartilage damage and arthropathy are reported in immature animals giving rise to concern over effects on bone formation in the developing fetus. Because safer alternatives are available, some experts consider Ofloxacin (Funzi MX) contraindicated during pregnancy, especially during the first trimester. The manufacturer only recommends use of Ofloxacin (Funzi MX) during pregnancy when benefit outweighs risk.
Of 549 cases reported by the European Network of Teratology Information Services involving fluoroquinolone exposure (including Ofloxacin (Funzi MX)), congenital malformations were reported in 4.8%; however, this was not higher than the background rate.
See references
Ofloxacin (Funzi MX) is excreted into human milk. Breast milk concentrations approximate maternal serum concentrations. Quinolone-induced cartilage erosion and arthropathies that have been observed in juvenile animals render some concern over its possible toxic effects on the developing joints of nursing infants. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
See references
Terbinafine (Funzi MX) has been assigned to pregnancy category B by the FDA. High dose reproduction studies in rats and rabbits have failed to reveal evidence of impaired fertility or fetotoxicity. There are no controlled data in human pregnancy. Because treatment of onychomycosis or tinea capitis can be postponed until after pregnancy is completed, the manufacturer recommends that Terbinafine (Funzi MX) not be started during pregnancy. Terbinafine (Funzi MX) is only recommended for use during pregnancy when benefit outweighs risk.
See references
Terbinafine (Funzi MX) is excreted into human milk following oral administration. The effects in the nursing infant are unknown. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
The ratio of Terbinafine (Funzi MX) in milk to plasma is 7:1.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|